These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 19739124)

  • 1. The effect of study arm on prostate cancer treatment in the large screening trial ERSPC.
    Wolters T; Roobol MJ; Steyerberg EW; van den Bergh RC; Bangma CH; Hugosson J; Ciatto S; Kwiatkowski M; Villers A; Luján M; Nelen V; Tammela TL; Schröder FH
    Int J Cancer; 2010 May; 126(10):2387-93. PubMed ID: 19739124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Could Differences in Treatment Between Trial Arms Explain the Reduction in Prostate Cancer Mortality in the European Randomized Study of Screening for Prostate Cancer?
    Carlsson SV; Månsson M; Moss S; Kwiatkowski M; Recker F; Tammela TLJ; Bangma C; Roobol MJ; Auvinen A; Hugosson J
    Eur Urol; 2019 Jun; 75(6):1015-1022. PubMed ID: 30928162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostate-specific antigen screening trials and prostate cancer deaths: the androgen deprivation connection.
    Haines IE; Gabor Miklos GL
    J Natl Cancer Inst; 2013 Oct; 105(20):1534-9. PubMed ID: 24092918
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term radical prostatectomy outcomes among participants from the European Randomized Study of Screening for Prostate Cancer (ERSPC) Rotterdam.
    Loeb S; Zhu X; Schroder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1678-83. PubMed ID: 22998182
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased non-prostate cancer death risk in clinically diagnosed prostate cancer.
    van Leeuwen PJ; Otto SJ; Kranse R; Roobol MJ; Bul M; Zhu X; de Koning H; Schröder FH
    BJU Int; 2012 Jul; 110(2):188-94. PubMed ID: 22288823
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differences in Treatment and Outcome After Treatment with Curative Intent in the Screening and Control Arms of the ERSPC Rotterdam.
    Bokhorst LP; Kranse R; Venderbos LD; Salman JW; van Leenders GJ; Schröder FH; Bangma CH; Roobol MJ;
    Eur Urol; 2015 Aug; 68(2):179-82. PubMed ID: 25457496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer mortality in the Finnish randomized screening trial.
    Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
    J Natl Cancer Inst; 2013 May; 105(10):719-25. PubMed ID: 23479454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease-specific survival of men with prostate cancer detected during the screening interval: results of the European randomized study of screening for prostate cancer-Rotterdam after 11 years of follow-up.
    Zhu X; van Leeuwen PJ; Bul M; Otto SJ; de Koning HJ; Bangma CH; Schröder FH; Roobol MJ
    Eur Urol; 2011 Aug; 60(2):330-6. PubMed ID: 21601352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update of the results of the Spanish branch of the European Randomized Study on Screening for Prostate Cancer (ERSPC).
    Luján M; Páez Á; Angulo JC; Andrés G; Gimbernat H; Redondo C; Torres GM; Berenguer A
    Actas Urol Esp; 2015 Sep; 39(7):405-13. PubMed ID: 25777669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Phase III trial to investigate the timing of radiotherapy for prostate cancer with high-risk features: background and rationale of the Radiotherapy -- Adjuvant Versus Early Salvage (RAVES) trial.
    Pearse M; Fraser-Browne C; Davis ID; Duchesne GM; Fisher R; Frydenberg M; Haworth A; Jose C; Joseph DJ; Lim TS; Matthews J; Millar J; Sidhom M; Spry NA; Tang CI; Turner S; Williams SG; Wiltshire K; Woo HH; Kneebone A
    BJU Int; 2014 Mar; 113 Suppl 2():7-12. PubMed ID: 24894850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radical prostatectomy vs radiation therapy and androgen-suppression therapy in high-risk prostate cancer.
    Westover K; Chen MH; Moul J; Robertson C; Polascik T; Dosoretz D; Katin M; Salenius S; D'Amico AV
    BJU Int; 2012 Oct; 110(8):1116-21. PubMed ID: 22540922
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impacts of a population-based prostate cancer screening programme on excess total mortality rates in men with prostate cancer: a randomized controlled trial.
    van Leeuwen PJ; Kranse R; Hakulinen T; Hugosson J; Tammela TL; Ciattoy S; Roobol MJ; Zappa M; de Koning HJ; Bangma CH; Moss SM; Auvinen A; Schröder FH
    J Med Screen; 2013 Mar; 20(1):33-8. PubMed ID: 23390203
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy.
    Messing EM; Manola J; Yao J; Kiernan M; Crawford D; Wilding G; di'SantAgnese PA; Trump D;
    Lancet Oncol; 2006 Jun; 7(6):472-9. PubMed ID: 16750497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Finnish prostate cancer screening trial: analyses on the screening failures.
    Kilpeläinen TP; Tammela TL; Malila N; Hakama M; Santti H; Määttänen L; Stenman UH; Kujala P; Auvinen A
    Int J Cancer; 2015 May; 136(10):2437-43. PubMed ID: 25359457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Roemeling S; Roobol MJ; Gosselaar C; Schröder FH
    Prostate; 2006 Jul; 66(10):1076-81. PubMed ID: 16637077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do Treatment Differences between Arms Affect the Main Outcome of ERSPC Rotterdam?
    Bokhorst LP; Venderbos LD; Schröder FH; Bangma CH; Steyerberg EW; Roobol MJ
    J Urol; 2015 Aug; 194(2):336-42. PubMed ID: 25698407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Change of tumour characteristics and treatment over time in both arms of the European Randomized study of Screening for Prostate Cancer.
    Boevee SJ; Venderbos LD; Tammela TL; Nelen V; Ciatto S; Kwiatkowski M; Páez A; Malavaud B; Hugosson J; Roobol MJ
    Eur J Cancer; 2010 Nov; 46(17):3082-9. PubMed ID: 21047590
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of prostate cancer].
    Romics I
    Orv Hetil; 2010 Apr; 151(14):580-3. PubMed ID: 20332076
    [No Abstract]   [Full Text] [Related]  

  • 20. Phase I-II trial evaluating combined intensity-modulated radiotherapy and in situ gene therapy with or without hormonal therapy in treatment of prostate cancer-interim report on PSA response and biopsy data.
    Teh BS; Ayala G; Aguilar L; Mai WY; Timme TL; Vlachaki MT; Miles B; Kadmon D; Wheeler T; Caillouet J; Davis M; Carpenter LS; Lu HH; Chiu JK; Woo SY; Thompson T; Aguilar-Cordova E; Butler EB
    Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1520-9. PubMed ID: 15050332
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.